<DOC>
	<DOC>NCT01332396</DOC>
	<brief_summary>Data on the safety and efficacy of TYKERB shall be collected from the patients in order to grasp the actual conditions of post-marketing use and assess background information on the patients.</brief_summary>
	<brief_title>Drug Use Investigation for TYKERB Tablet (All Case Investigation)</brief_title>
	<detailed_description />
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Patients with HER2 overexpressing inoperable or recurrent breast cancer Patients with hypersensitivity to lapatinib or any components Pregnant women and women suspected of being pregnant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>